Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral...
Parkinson's DiseaseThe primary objectives of the trial are to assess the safety and efficacy of ProSavin. Patients in the trial will have been diagnosed with Parkinson's disease and will be failing on current treatment with L-DOPA but they will not have progressed to drug-induced dyskinesias. The first stage is an open-label dose escalation to evaluate up to three dose levels of ProSavin in cohorts of three patients each. Following a recommendation by the DMC the study may proceed to the second stage of the trial, a further 12 patients will be recruited to confirm efficacy of the optimal dose in the randomized phase of the study. The efficacy of ProSavin will be assessed using the Unified Parkinson's Disease Rating Score (UPDRS). Patients will be monitored at regular intervals, with the primary endpoint being an efficacy assessment at six months after treatment. The secondary objective of the trial is to asses the extent to which patients' current therapy (L-DOPA) can be reduced following administration of ProSavin.
Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With...
Idiopathic Parkinson's DiseaseTo evaluate the safety and efficacy of two dose ranges of safinamide (High Dose: 150 to 200 mg/day and Low Dose: 50 to 100 mg/day) orally, as compared to Placebo, as add-on therapy in patients with early idiopathic Parkinson's disease who are currently receiving a stable dose of a single dopamine agonist. It is hypothesized that, over a 24-week period, add-on treatment with safinamide will result in greater improvement of motor symptoms in these patients, compared to treatment with a dopamine agonist alone.
Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
Parkinson's DiseaseTo evaluate the effects of Memantine on non-motor symptoms in patients with Parkinson's disease. Parkinson's disease (PD) affects about one million people in the United States. It is a common neurological condition that is clinically defined by rigidity (muscle stiffness), bradykinesia (slowness of movement) and tremor. Parkinson's Disease , however, reveals numerous non-motor symptoms that have been underemphasized. Problematic symptoms include varying degrees of dementia, psychosis, diminished assertiveness and confidence, general fatigue, excessive daytime sleepiness, problems with blood pressure, sweating, and bladder, and a common yet difficult to define sense of "not feeling well".
Safety Study of Subthalamic Nucleus Gene Therapy for Parkinson's Disease
Parkinson's DiseaseThe purpose of this study is to determine the safety of using a modified virus to transfer a gene called GAD into a region of the brain called the subthalamic nucleus in patients with advanced Parkinson's disease. The overall goal of this approach is to ultimately normalize the flow of information in several brain regions responsible for movement, to ultimately improve function in patients with this disorder. The current study is primarily designed to evaluate the safety of this approach, but patients are also being monitored for possible signs of effectiveness as well.
A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's...
Parkinson's DiseaseA 2 phase study to evaluate disease progression in Parkinson's disease patients taking rasagiline
Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease...
Parkinson DiseaseThe primary objective is to assess the effect of SR57667B at the dose of 4 mg/d on the progression of Parkinson symptoms in patients with early PD. The primary outcome will be the time to progression of disability warranting initiation of L-dopa or a dopamine agonist. Secondary outcomes will comprise assessments of symptoms, activities of daily living and global clinical status.
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination...
Parkinson's DiseasePatients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD: Group 1 Patients using Azilect and no other therapy. Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or Requip.
Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients...
Parkinson's DiseaseThis is a study to look at the effectiveness, tolerability, and safety of one dose of rasagiline in advanced Parkinson's disease (PD) patients who have been treated with Levodopa/Carbidopa therapy.
Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications...
Parkinson's DiseaseThe purpose of this study is to confirm the long term tolerability and safety of oral 20 or 40 mg/d doses of Istradefylline.
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
Parkinson's DiseaseThe purpose of this study is to evaluate the efficacy of 40 mg a day of istradefylline (KW-6002) for reducing the percentage of awake time spent in the OFF state in patients with advanced Parkinson's disease treated with levodopa.